| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/17/2010 | EP2152267A2 Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles |
| 02/17/2010 | EP2152256A2 Telomerase activating compounds and methods of use thereof |
| 02/17/2010 | EP1893213B1 Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases |
| 02/17/2010 | EP1549322B1 Lipid a and other carbohydrate ligand analogs |
| 02/17/2010 | EP1511737B1 Aryloximes |
| 02/17/2010 | EP1420775B1 Platinum complexes and their uses in therapy |
| 02/17/2010 | EP1071700B1 Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| 02/17/2010 | CN101649351A Methods for diagnosis and therapy of cancer and composition useful therein |
| 02/17/2010 | CN100590196C Branched neutral amino acid transporters acting as single molecule |
| 02/17/2010 | CN100590131C Methods and compounds for the targeting of protein to exosomes |
| 02/17/2010 | CN100590124C Tricyclic androgen receptor modulator compounds and method |
| 02/17/2010 | CN100590118C Novel style heterocyclic compound as insulin-like growth factors first type acceptor inhibitor |
| 02/17/2010 | CN100589845C Anti-neovasculature preparations for cancer |
| 02/17/2010 | CN100589812C Plant worms mycelium extracat fraction and composition for oral intake |
| 02/17/2010 | CN100589806C Use of steroid derivatives for the treatment of angiotensin II related disease e.g. cardiovascular and proliferative disorders |
| 02/16/2010 | US7662976 Triptolide derivatives for modulation of apoptosis and immunosuppression |
| 02/16/2010 | US7662974 Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same |
| 02/16/2010 | US7662948 Antisense oligonucleotides against VR1 |
| 02/16/2010 | US7662938 2′-fluoronucleosides |
| 02/16/2010 | US7662933 Pegylated granulocyte colony stimulating factor (G-CSF) to treat a hematopoietic disorder related to reduced neutrophil count, such as infectious disease, sepsis, or a result of radiotherapy or chemotherapy |
| 02/16/2010 | US7662929 Enzyme is a drug target; cancer, inflammatory diseases such as psoriasis |
| 02/16/2010 | US7662854 HIF hydroxylase inhibitors |
| 02/16/2010 | US7662853 Monoacetyldiacylglycerol derivative for the treatment of sepsis |
| 02/16/2010 | US7662851 Use of specific cyklolignans |
| 02/16/2010 | US7662849 N-cyanomethyl-2R-[(benzenesulfonyliminomethyl)amino]-3-(2-difluoromethoxyphenylmethanesulfonyl)-propionamide; treating autoimmune disorders |
| 02/16/2010 | US7662845 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12 |
| 02/16/2010 | US7662843 Isoxazoline compounds having MIF antagonist activity |
| 02/16/2010 | US7662825 2,3-Dichloro-N-(3-methoxy-5-methyl-2-pyrazinyl)-benzenesulphonamide; inflammatory diseases, such as asthma |
| 02/16/2010 | US7662820 Dipterinyl calcium pentahydrate (DCP) and therapeutic methods based thereon |
| 02/16/2010 | US7662819 Pteridinone derivatives for use as stearoyl CoA desaturase inhibitors |
| 02/16/2010 | US7662814 4-(4-Ethylpiperazin-1-yl)-5-methyl-2-phenylthieno[2,3-d]pyrimidine-6-carbonitrile; asthma, atopic dermatitis, chronic obstructive pulmonary disease, Crohn's disease, type I and type II diabetes, lymphoid leukemia and other forms of cancer, multiple sclerosis and autoimmune diseases |
| 02/16/2010 | US7662807 Sulphonated meso-tetraphenyl chlorins |
| 02/16/2010 | US7662786 Dolastatin 15 derivatives |
| 02/16/2010 | US7662778 a compound containing cyclic tetrapeptide coupled to amide, ester, ketone groups; apoptosis and cell differentiation inducer; cancer metastasis and angiogenesis inhibitor; catalytic hydrogenation, acid treatment, fluoride anion treatment, or hydrolysis for deblocking; coupling cyclic tertrapeptide |
| 02/16/2010 | US7662767 inhibiting complexation of intercalating molecules with polynucleotides; using modified xanthine molecules as a binding agent; drug delivery system for compounds that have low solubility in aqueous media, including anti-neoplastic agents |
| 02/16/2010 | US7662633 Method of screening for inhibitors of osteopontin |
| 02/16/2010 | US7662620 Stem cell-derived neuron survival factor polypeptides (SDNSF) for use in prevention and treatment of cell proliferative, neurodegenerative and cardiovascular disorders |
| 02/16/2010 | US7662553 Polymorphisms in the ERCC1 gene for predicting treatment outcome |
| 02/16/2010 | US7662408 Sustained-release preparations |
| 02/16/2010 | US7662395 Recombinant virus encoding an antigen of a disease state; second recombinant virus encoding an immunostimulatory molecule with an exogenous immunostimulatory molecule, chemotherapeutic drug, antibiotic, antiviral drug or antifungal drug. |
| 02/16/2010 | US7662392 Stromal-Derived Factor-1 (SDF), G-CSF (granulocyte-colony stimulating factor), stimulating vasculogenesis; improves cardiac function |
| 02/16/2010 | US7662380 ZAQ ligand-1 antibodies and uses thereof |
| 02/16/2010 | US7662374 Dual-specificity antibody having specificity for both an activated erbB2 receptor and erbB1 dimers, without significant affinity for monomeric EGFr that is not activate; specificity of the antibodies is due to their recognition and binding of activation epitopes; diagnosis, imaging and for treating tumor |
| 02/16/2010 | CA2571627C Substituted aryl-amine derivatives and methods of use |
| 02/16/2010 | CA2450922C Piperidines for use as orexin receptor antagonists |
| 02/16/2010 | CA2440037C Benzimidazole derivatives for modulating the rage receptor |
| 02/16/2010 | CA2407043C Naphthamidine urokinase inhibitors |
| 02/16/2010 | CA2406095C Synthetic process for the manufacture of an ecteinaschidin compound |
| 02/16/2010 | CA2402436C Amidino compound and salts thereof useful as nitric oxide synthase inhibitors |
| 02/16/2010 | CA2371912C Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| 02/16/2010 | CA2287387C Methods and compositions for destruction of selected proteins |
| 02/16/2010 | CA2223701C Fgf9 as a specific ligand for fgfr3 |
| 02/11/2010 | WO2010017550A2 Lipid compounds for supression of tumorigenesis |
| 02/11/2010 | WO2010017545A2 Triazole compounds that modulate hsp90 activity |
| 02/11/2010 | WO2010017443A2 Anti-beta-2-microglobulin agents and the use thereof |
| 02/11/2010 | WO2010017317A2 Use of mtor inhibitors to enhance t cell immune responses |
| 02/11/2010 | WO2010017240A2 Aurora kinase modulators and methods of use |
| 02/11/2010 | WO2010017163A1 Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
| 02/11/2010 | WO2010017051A1 Novel phenylamino isonicotinamide compounds |
| 02/11/2010 | WO2010017035A2 Inhibitors of iap |
| 02/11/2010 | WO2010016806A1 Vhz for diagnosis and treatment of cancers |
| 02/11/2010 | WO2010016581A1 Ultrasonic cancer therapy accelerator |
| 02/11/2010 | WO2010016549A1 Tricyclic compound |
| 02/11/2010 | WO2010016526A1 Pharmaceutical composition for treatment and prevention of cancer |
| 02/11/2010 | WO2010016525A1 Immunity inducer |
| 02/11/2010 | WO2010016490A1 Imidazopyridin-2-on derivative |
| 02/11/2010 | WO2010016011A1 Organosulfur compounds, a method of making organosulfur compounds and their use for inhibiting the growth of tumour cells |
| 02/11/2010 | WO2010016005A1 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors |
| 02/11/2010 | WO2010015874A1 Pharmaceutical uses of lanosta-8,24-dien-3-ols |
| 02/11/2010 | WO2010015792A1 Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors |
| 02/11/2010 | WO2010015704A1 Pharmaceutical compositions comprising antibodies binding to ebv (epstein-barr virus) protein barf1 |
| 02/11/2010 | WO2010015590A1 Organotin(iv) complexes with n-acetylcysteine possessing antitumoral activity, process for their production and their use |
| 02/11/2010 | WO2010015523A1 Cyclohexyloxy-substituted heterocyclics, medicines containing these compounds and method for the production thereof |
| 02/11/2010 | WO2010015522A1 Cyclohexyloxy-substituted heterocyclics, medicines containing these compounds and method for the production thereof |
| 02/11/2010 | WO2010015090A1 Functionalized pyrrolidines and use thereof as iap inhibitors |
| 02/11/2010 | WO2010015036A1 Biological applications of steroid binding domains |
| 02/11/2010 | WO2009155070A3 Compositions and methods for treatment of inflammation and hyperkeratotic lesions |
| 02/11/2010 | WO2009123764A3 Compositions and use of epas1 inhibitors |
| 02/11/2010 | WO2009001219A9 Immunocytokines for cancer treatment in combination with chemotherapeutic agents |
| 02/11/2010 | US20100037328 Cd20-negatively converted b cell malignant lymphocyte cell line and utilization of the same |
| 02/11/2010 | US20100035982 Oxaliplatin formulations |
| 02/11/2010 | US20100035976 Method of treating a tumor or a viral disease by administering a 2' , 5' -oligoadenylate analog |
| 02/11/2010 | US20100035970 Methylation Markers for Diagnosis and Treatment of Cancers |
| 02/11/2010 | US20100035959 Novel sphingosine kinase type 1 inhibitors, compositions and processes for using same |
| 02/11/2010 | US20100035952 Radiosensitizer Formulations and Methods for Use |
| 02/11/2010 | US20100035946 Indoline anti-cancer agents |
| 02/11/2010 | US20100035943 Oxa-and thiadiazoles and their use as metalloproteinase inhibitors |
| 02/11/2010 | US20100035934 Pyridinyl-pyrazole derivatives and their use as potassium channel modulators |
| 02/11/2010 | US20100035932 Novel formyl peptide receptor like 1 agonists that induce macrophage tumor necrosis factor alpha and computational structure-activity relationship analysis of thereof |
| 02/11/2010 | US20100035929 Unnatural dispyrin analogues, preparation and uses thereof |
| 02/11/2010 | US20100035918 Imidazolone Compounds and Methods of Making and Using the Same |
| 02/11/2010 | US20100035911 Drug combinations to treat hyperproliferative disorders |
| 02/11/2010 | US20100035908 Substituted acetophenones useful as pde4 inhibitors |
| 02/11/2010 | US20100035907 New 2,4-dianilinopyrimidines, preparation thereof as drugs, pharmaceutical compositions and use thereof essentially as ikk inhibitors |
| 02/11/2010 | US20100035903 administering 3-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile or salts, for the treatment of dermatitis, Crohn's disease, inflammatory bowel disease, transplant rejection, lupus, multiple sclerosis, arthritis, psoriasis, diabetes and autoimmune diseases |
| 02/11/2010 | US20100035896 Combination of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an anti-mitotic cytotoxic agent |
| 02/11/2010 | US20100035891 Pharmaceutically Active Compounds |
| 02/11/2010 | US20100035885 Compositions for manipulating the lifespan and stress response of cells and organisms |
| 02/11/2010 | US20100035883 Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) |
| 02/11/2010 | US20100035879 N-sulfonylcarboximidamide apoptosis promoters |